Shares of Bio-Techne Corp. advanced 6.51% to $55.63 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.41% to 6,688.46 and the ...

Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including ...

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2026 results , with sales up 1.3% year on year to $321.2 million. Its non-GAAP profit of $0.52 per share was in line with analysts’ ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

WASHINGTON (dpa-AFX) - Bio-Techne Corporation's (TECH) activist investor Ananym Capital Management has taken a stake in the company and is urging management to explore strategic alternatives, ...

Bio-Techne also expanded its use of renewable electricity during the year. The company transitioned its Minneapolis headquarters to 100% renewable electricity and began procuring renewable electricity ...

The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...

A German company that provides products and services that accelerate drug development and manufacturing is set to acquire the Minneapolis-based group Bio-Techne, according to a news release posted ...

Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...